FdaApplication
BLA 761291
Identifiers
- fda_app_no: BLA761291
Properties
| Property | Value |
|---|---|
| applicant_name | Janssen Biotech, Inc. |
| application_type | BLA |
| approval_date | 2022-10-25 |
Revenue by product
TECVAYLI
| Period | Revenue |
|---|---|
| Q2 2026 | $260.0M |
| Q1 2026 | $202.0M |
| Q3 2025 | $177.0M |
| Q2 2025 | $166.0M |
| Q1 2025 | $151.0M |
| Q3 2024 | $135.0M |
| Q2 2024 | $135.0M |
| Q1 2024 | $133.0M |
| Q3 2023 | $112.0M |
| Q2 2023 | $94.0M |
| Q1 2023 | $63.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TECVAYLI | TECLISTAMAB-CQYV | 153MG/1.7ML (90MG/ML) | Injection |
| TECVAYLI | TECLISTAMAB-CQYV | 30MG/3ML (10MG/ML) | Injection |
2 products